Tirzepatide (Zepbound)

Peptide

Approvedregulatory verdict

Evidence outlook

Approved: Obesity

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Psoriasis · Phase 3Psoriatic Arthritis · Phase 3Crohn's Disease · Phase 3

Also approved (5)
US
  • Moderate to severe obstructive sleep apnea (OSA) in adults with obesity (Zepbound)FDA label
  • Zepbound: to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesityFDA label
Product first approved 2023
JP
  • Zepbound: obesity disease
Product first approved 2024pj.jiho.jp
EU
  • Mounjaro: weight management indication (extension)
EMA
CA
  • ZEPBOUND (tirzepatide injection) is indicated for once-weekly administration as an adjunct to a reduced-calorie diet and increased physical activity: • for chronic weight management, including weight loss and weight maintenance in adults with an initial body mass index (BMI) of: • 30 kg/m2 or greater (obesity) or • 27 kg/m2 to less than 30 kg/m2 (overweight) in the presence of at least one weight- related comorbid condition (e.g., hypertension, dyslipidemia, prediabetes, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease). • to treat moderate to severe obstructive...
Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (28)
Crohn's Disease
NCT06937099 · Eli Lilly and Company
2025-06-26 – 2028-05 · Crohn's Disease, Obesity or Overweight
What this study did
Obesity
NCT06439277 · Eli Lilly and Company
2024-06-03 – 2030-12 · Obesity, Weight Gain
What this study did
NCT07881432 · Eli Lilly and Company
2026-12 – 2029-11 · Obesity
What this study did
NCT07881458 · Eli Lilly and Company
2026-10-16 – 2029-11 · Obesity, Overweight, Diabetes Mellitus, Type 2
What this study did
NCT06075667 · Eli Lilly and Company
2023-10-16 – 2029-07 · Obesity, Overweight
What this study did
NCT06937086 · Eli Lilly and Company
2025-06-26 – 2028-04 · Ulcerative Colitis, Obesity or Overweight
What this study did
NCT07481747 · Hudson Biotech
2026-02-02 – 2028-03-17 · Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
What this study did
NCT07738276 · Shahid Beheshti University of Medical Sciences
2026-07-18 – 2027-12-22 · Heart Failure and Reduced Ejection Fraction, Obesity & Overweight, Tirzepatide
What this study did
NCT05556512 · Eli Lilly and Company
2022-10-11 – 2027-10 · Obesity, Overweight
What this study did
NCT06962280 · Eli Lilly and Company
2025-05-12 – 2027-07 · Type 1 Diabetes, Obesity, Overweight
What this study did
NCT06914895 · Eli Lilly and Company
2025-04-25 – 2026-12 · Type 1 Diabetes, Obesity, Overweight
What this study did
NCT06918405 · Chittagong Medical College
2025-01-01 – 2026-06-30 · Obesity and Obesity-related Medical Conditions
What this study did
NCT07834398 · Zagazig University
2025-11-14 – 2026-04-21 · Non-diabetec Obesity, Obesity (Disorder)
What this study did
NCT07820111 · Zagazig University
2025-10-18 – 2026-03-17 · Obese Diabetics, Obese Non Diabetic
What this study did
NCT06047548 · Eli Lilly and Company
2023-09-20 – 2026-01-20 · Overweight, Obesity
What this study did
NCT05822830 · Eli Lilly and Company
2023-04-21 – 2024-11-13 · Obesity, Overweight
What this study did
NCT04847557 · Eli Lilly and Company
2021-04-20 – 2024-07-02 · Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
What this study did
NCT04844918 · Eli Lilly and Company
2021-05-10 – 2023-06-24 · Obesity
What this study did
NCT05024032 · Eli Lilly and Company
2021-09-01 – 2022-12-27 · Obesity, Overweight, Metabolism and Nutrition Disorder
What this study did
Psoriasis
NCT06588283 · Eli Lilly and Company
2024-09-30 – 2026-06-01 · Psoriasis, Obesity
What this study did
Psoriatic Arthritis
NCT06588296 · Eli Lilly and Company
2024-09-24 – 2026-04-23 · Psoriatic Arthritis, Obesity
What this study did
Phase 2/3 (2)
Obesity
NCT07846865 · Woolcock Institute of Medical Research
2026-10-01 – 2028-12-01 · Sleep Apnoea, Obesity & Overweight, Sleep Apnea Syndrome, Obstructive
What this study did
NCT06162715 · Vanderbilt University Medical Center
2024-10-30 – 2027-04-30 · Severe Obesity, Obesity, BMI Greater Than 30
What this study did
Phase 2 (30)
Obesity
NCT06517212 · Baylor Research Institute
2024-11-26 – 2030-12-31 · Breast Cancer, Breast Neoplasms, Breast Cancers
What this study did
NCT07349641 · National Cancer Institute (NCI)
2026-11-01 – 2030-10-31 · Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
What this study did
NCT07693608 · University of Texas Southwestern Medical Center
2026-08-19 – 2030-03-01 · Obesity, Methamphetamine Use Disorder, Cocaine Use Disorder, Stimulant Use Disorders
What this study did
NCT05912621 · Stanford University
2023-11-09 – 2029-12 · Obesity, Overweight and Obesity, Overweight
What this study did
NCT07747805 · The Cleveland Clinic
2026-08-28 – 2029-08-15 · COPD, Obesity & Overweight, Sarcopenia
What this study did
NCT06582875 · University of Colorado, Denver
2025-03-06 – 2029-06-30 · Autosomal Dominant Polycystic Kidney, Obesity
What this study did
NCT07078838 · UNC Lineberger Comprehensive Cancer Center
2027-01 – 2029-03 · Endometrial Cancer, Endometrial Intraepithelial Neoplasia, Grade 1 Endometrial Endometrioid Carcinoma
What this study did
NCT06180616 · Royal North Shore Hospital
2026-12 – 2028-12 · Type 1 Diabetes Mellitus, Overweight and Obesity
What this study did
NCT07228741 · St. Jude Children's Research Hospital
2026-04-23 – 2028-11 · Acute Lymphoblastic Leukemia, Obesity
What this study did
NCT06143956 · Eli Lilly and Company
2023-11-17 – 2028-02 · Obesity, Overweight
What this study did
NCT07292519 · South West Sydney Local Health District
2026-01-15 – 2028-01-15 · Alcohol Use Disorder (AUD), Overweight or Obese, Comorbidities and Coexisting Conditions
What this study did
NCT06732245 · Biomed Industries, Inc.
2026-08-15 – 2027-12-15 · Obesity and Overweight
What this study did
NCT06847399 · Johns Hopkins University
2025-09-17 – 2027-12-01 · Obesity and Overweight, Binge Eating Disorder
What this study did
NCT07671391 · Shanghai Zhongshan Hospital
2026-08 – 2027-12 · Obesity Adult Onset
What this study did
NCT06518837 · Rutgers, The State University of New Jersey
2024-10-30 – 2027-09-30 · Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
What this study did
NCT06802081 · The Cleveland Clinic
2025-04-08 – 2027-06-01 · Atrial Fibrillation, Obesity
What this study did
NCT06811324 · The University of Texas Health Science Center at San Antonio
2026-04-01 – 2027-06-01 · Obesity Prevention, Sarcopenia in Elderly, Cardiovascular Function, GLP - 1, Weight Loss
What this study did
NCT06965413 · Hoffmann-La Roche
2025-05-05 – 2027-03-31 · Obesity, Overweight, Overweight With One Weight Related Comorbidity
What this study did
NCT07179120 · First Affiliated Hospital of Wenzhou Medical University
2026-05-01 – 2027-01-02 · Obesity-related Male Infertility
What this study did
NCT06037252 · Eli Lilly and Company
2023-09-21 – 2026-10 · Type 2 Diabetes, Obesity
What this study did
NCT06994338 · University of Southern California
2025-10-06 – 2026-08-31 · Alcohol Use Disorder, Obesity and Overweight, Alcohol
What this study did
NCT05536804 · Eli Lilly and Company
2023-02-08 – 2026-07-30 · Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
What this study did
NCT06935838 · University of Hawaii
2025-11-12 – 2026-06-02 · Obesity and Overweight, HIV, Chronic Inflammation
What this study did
NCT06373146 · Eli Lilly and Company
2024-04-24 – 2026-04-02 · Obesity
What this study did
NCT06745128 · University of Texas Southwestern Medical Center
2025-02-03 – 2026-02-12 · Obesity, Methamphetamine Use Disorder
What this study did
NCT06893211 · University Medical Centre Ljubljana
2025-03-18 – 2025-12-20 · Obesity
What this study did
NCT06901349 · Eli Lilly and Company
2025-05-23 – 2025-06-10 · Obesity, Overweight
What this study did
NCT06565611 · Palatin Technologies, Inc
2024-08-05 – 2025-03-31 · Obesity
What this study did
Phase 1/2 (1)
Obesity
NCT07463846 · Alnylam Pharmaceuticals
2026-03-02 – 2028-04-28 · Obesity
What this study did
Phase 1 (19)
Obesity
NCT06759701 · M.D. Anderson Cancer Center
2025-07-02 – 2028-12-31 · Diabetes, Prostate Cancer
What this study did
NCT06734273 · Nicholas Skertich
2025-03-10 – 2028-09 · Obesity and Obesity-related Medical Conditions
What this study did
NCT07065552 · UNC Lineberger Comprehensive Cancer Center
2026-04-27 – 2028-07 · Endometrial Cancer, Obesity
What this study did
NCT06751589 · Memorial Sloan Kettering Cancer Center
2024-12-19 – 2027-12 · Endometrial Cancer
What this study did
NCT06575738 · University of Colorado, Denver
2024-10-11 – 2027-10-01 · Obesity, Adolescent Obesity, Body-Weight Trajectory, Weight Loss Trajectory, Bariatric Surgery, Anti-obesity Agents
What this study did
NCT05822544 · OrsoBio, Inc
2023-04-22 – 2027-01 · Healthy Subjects, Obesity, Type 2 Diabetes
What this study did
NCT07803744 · Eli Lilly and Company
2026-09-11 – 2026-12 · Diabetes Mellitus, Type 1, Overweight, Obesity
What this study did
NCT06934642 · University of New Mexico
2025-06-30 – 2026-10 · MASLD, Obesity
What this study did
NCT06916065 · Eli Lilly and Company
2025-04-09 – 2026-01-19 · Overweight, Obesity
What this study did
NCT06297616 · Eli Lilly and Company
2024-04-15 – 2025-11-21 · Obesity, Overweight
What this study did
NCT06345066 · Eli Lilly and Company
2024-04-03 – 2025-09-29 · Obesity, Overweight
What this study did
NCT05696847 · Eli Lilly and Company
2023-02-07 – 2025-01-16 · Obesity
What this study did
NCT05582096 · Eli Lilly and Company
2022-11-11 – 2023-06-08 · Overweight, Obesity
What this study did
NCT04311411 · Eli Lilly and Company
2020-08-24 – 2022-12-16 · Obesity, Overweight
What this study did
NCT04081337 · Eli Lilly and Company
2020-07-09 – 2022-05-26 · Obesity
What this study did
NCT04407234 · Eli Lilly and Company
2020-09-15 – 2021-01-07 · Overweight, Obesity, Diabetes Mellitus, Type 2
What this study did
Phase 4 (28)
Obesity
NCT06191848 · University of Melbourne
2024-11-19 – 2037-05 · Obesity, Knee Osteoarthritis, Osteoarthritis, Knee
What this study did
NCT07247084 · Eli Lilly and Company
2025-11-24 – 2032-07 · Obesity
What this study did
NCT07554638 · Columbia University
2026-08-07 – 2030-04 · Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity
What this study did
NCT07900074 · McMaster University
2026-10-31 – 2029-12-31 · Obesity (Disorder)
What this study did
NCT07715929 · Yunlong Wang
2026-09-01 – 2029-12-30 · Atrial Fibrillation, Obesity & Overweight, Catheter Ablation
What this study did
NCT07630454 · Yunlong Wang
2026-08-01 – 2029-12-01 · Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFpEF), Tirzepatide
What this study did
NCT07326111 · University of Bonn
2025-12-09 – 2029-12 · Polycystic Ovary Syndrome (PCOS), Obesity & Overweight
What this study did
NCT06606821 · Tina Vilsbøll
2024-10-01 – 2028-08-01 · Coronary Artery Disease, Coronary Microvascular Dysfunction, Overweight or Obesity, Stable Angina Pectoris, Chronic Coronary Artery Disease, Atherosclerosis Cardiovascular Disease
What this study did
NCT07096908 · Dasman Diabetes Institute
2025-07-31 – 2028-08-01 · Type1diabetes, Obesity
What this study did
NCT06854614 · The Cleveland Clinic
2025-03-01 – 2028-04-28 · Obesity
What this study did
NCT07257484 · Weill Medical College of Cornell University
2026-06-08 – 2028-02-25 · Obesity (Disorder), Breast Cancer
What this study did
NCT07354880 · University Medical Centre Ljubljana
2026-01-20 – 2027-12-31 · Obesity & Overweight, Adult Congenital Heart Disease
What this study did
NCT06861439 · Wake Forest University Health Sciences
2025-07-07 – 2027-12-31 · Obesity
What this study did
NCT06803888 · Ali Aminian
2025-01-29 – 2027-12-01 · Obesity and Obesity-related Medical Conditions
What this study did
NCT07707778 · National Taiwan University Clinical Trial Center
2026-06-25 – 2027-12 · Human Immunodeficiency Virus (HIV), Metabolic Dysfunction Associated Steatotic Liver Disease, Dyslipidaemia, Diabetes Mellitus, Obesity & Overweight, Metabolic Syndrome
What this study did
NCT07893457 · Mayo Clinic
2026-10-26 – 2027-10-26 · Obese Adults
What this study did
NCT07218445 · Mayo Clinic
2026-04-08 – 2027-09-18 · Obesity, Menopause Hot Flashes
What this study did
NCT07588438 · Las Rías Medical Center
2026-07-27 – 2027-08-10 · Obesity, Diabetes Mellitus, Type 2
What this study did
NCT07438444 · Eli Lilly and Company
2026-02-27 – 2027-07 · Diabetes Mellitus, Type 2, Obesity, Overweight
What this study did
NCT07154719 · Pennington Biomedical Research Center
2025-10-09 – 2027-05-01 · Musculoskeletal Abnormalities, Obesity, Sarcopenic Obesity, Osteoporosis, Drug Effect
What this study did
NCT07057310 · Mayo Clinic
2025-05-01 – 2027-03-31 · Obesity, Menopause
What this study did
NCT06721507 · Marlene Starr
2025-03-27 – 2026-12-31 · Obesity and Obesity-related Medical Conditions, Bariatric Surgery
What this study did
NCT06901245 · Grace Kim
2025-05-01 – 2026-12 · Prader-Willi Syndrome, Hypothalamic Obesity, Obesity/Therapy
What this study did
NCT07423247 · Shahid Beheshti University of Medical Sciences
2026-01-01 – 2026-09 · Tirzepatide
What this study did
NCT06009653 · Washington University School of Medicine
2023-09-13 – 2024-05-29 · Obesity, Metabolic Disease
What this study did
Psoriasis
Psoriatic Arthritis
NCT06864026 · Eli Lilly and Company
2025-03-06 – 2027-08 · Psoriatic Arthritis, Overweight or Obesity
What this study did
Early phase / not applicable (17)
Obesity
NCT06885736 · Dasman Diabetes Institute
2025-08-07 – 2029-12-31 · Obesity
What this study did
NCT07574723 · Dasman Diabetes Institute
2026-05-15 – 2029-12-31 · Obesity
What this study did
NCT07589322 · Tri-Service General Hospital (TSGH)
2026-03-31 – 2029-09-30 · Obesity and Metabolic Syndrome
What this study did
NCT07387796 · The University of Texas at Dallas
2026-10 – 2029-02 · Drug Discontinuation, Substance Use Disorders, Eating Behavior Changes, Tirzepatide
What this study did
NCT07364175 · Cambridge University Hospitals NHS Foundation Trust
2026-01 – 2029-01 · Hypertension, Obesity & Overweight
What this study did
NCT07382024 · National Taiwan University Hospital
2026-06-16 – 2028-07-31 · Atrial Fibrillation Ablation, Persistent Atrial Fibrillation, Obesity & Overweight
What this study did
NCT07728318 · Akhtar Saeed Medical and Dental College
2027-12-12 – 2028-05-12 · Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
What this study did
NCT07633639 · China-Japan Friendship Hospital
2026-05-01 – 2028-05-01 · Obesity
What this study did
NCT07866183 · National Medical Research Center for Therapy and Preventive Medicine
2026-06-29 – 2027-08 · Class I Obesity
What this study did
NCT07293325 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-06-02 – 2027-06-02 · Adults With Simple Obesity
What this study did
NCT07685834 · Sofwave Medical LTD
2026-02-27 – 2027-03-01 · Lax Skin
What this study did
NCT07373834 · University Medical Centre Ljubljana
2026-01 – 2027-03 · Obesity (Disorder)
What this study did
NCT06484114 · Fractyl Health Inc.
2024-09-01 – 2027-02-26 · Obesity, Weight Change Trajectory, Weight Change, Body
What this study did
NCT07740291 · Texas Tech University
2025-01-02 – 2026-12-07 · Obesity & Overweight, Cardiometabolic Health Indicators, Addiction, Eating Disorders, Mental Health
What this study did
NCT07319975 · Istanbul Galata University
2025-12-29 – 2026-12 · Obesity
What this study did
NCT07176663 · Shahid Beheshti University of Medical Sciences
2026-02-01 – 2026-05-01 · Obesity
What this study did
Psoriatic Arthritis
NCT07443956 · NHS Greater Glasgow and Clyde
2026-03-09 – 2030-05 · Psoriatic Arthritis (PsA), Obesity & Overweight
What this study did
Used as active comparator (16)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (3)
Obesity
NCT07845500 · Pfizer
2026-09-30 – 2028-02-16 · Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity
What this study did
NCT06662383 · Eli Lilly and Company
2024-11-01 – 2026-12 · Obesity
What this study did
NCT06131437 · Novo Nordisk A/S
2023-11-27 – 2026-01-09 · Obesity
What this study did
Phase 2 (7)
Obesity
NCT05933499 · Massachusetts General Hospital
2025-11-05 – 2029-03-31 · Obesity
What this study did
NCT07521631 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2026-03-31 – 2027-07-23 · Obesity
What this study did
NCT06643728 · Eli Lilly and Company
2024-10-21 – 2026-10-27 · Obesity, Overweight
What this study did
NCT06737042 · Gan and Lee Pharmaceuticals, USA
2025-02-24 – 2026-02-27 · Obesity and Overweight
What this study did
NCT06911203 · BrightGene Bio-Medical Technology Co., Ltd.
2025-04-09 – 2026-01-14 · Obesity
What this study did
NCT06326060 · Novo Nordisk A/S
2024-03-18 – 2025-05-01 · Obesity
What this study did
Phase 1/2 (3)
Obesity
NCT06700538 · Arrowhead Pharmaceuticals
2024-12-04 – 2028-02-15 · Obesity
What this study did
NCT07000955 · Innovent Biologics (Suzhou) Co. Ltd.
2025-06-17 – 2027-05-14 · Obesity
What this study did
Phase 1 (1)
Obesity
NCT07842640 · Ascletis Pharma (China) Co., Limited
2026-08-27 – 2027-06 · Chronic Weight Management
What this study did
Phase 4 (2)
Obesity
NCT07555730 · Huazhong University of Science and Technology
2026-04-30 – 2028-09-30 · Overweight or Obesity; Type 2 Diabetes, Weight Loss Maintenance
What this study did
NCT07697391 · The First Affiliated Hospital of Anhui Medical University
2026-07-16 – 2028-01-31 · Obesity, Diabetes Mellitus, Type 2
What this study did
Appears in other studies (4)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Obesity
NCT07943754 · Wake Forest University Health Sciences
2027-06 – 2031-11 · Obesity
What this study did
NCT07298915 · University of Virginia
2026-08 – 2027-06 · Obesity & Overweight
What this study did
Phase 2 (1)
Obesity
NCT06445075 · Scholar Rock, Inc.
2024-05-21 – 2025-06-17 · Overweight and Obesity
What this study did
Phase 4 (1)
Obesity
NCT07777575 · Technical University of Munich
2026-10-07 – 2027-08-31 · Obesity (BMI>30)
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Obesity: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tirzepatide (Zepbound): this drugApprovedPeptideGLP-1/GIP receptor (dual)Reliable signal
NCT05412004: Change From Baseline in Apnea-Hypopnea Index (AHI) (Baseline, Week 52): Tirzepatide MTD_GPI1 -25.25 events per hour (Standard Error 2.06) | Placebo_GPI1 -5.25 events per hour (Standard Error 2.11) | Tirzepatide MTD_GPI2 -29.27 events per hour (Standard Error 1.99) | Placebo_GPI2 -5.51 events per hour (Standard Error 2.21)
NCT04660643: Percent Change From Randomization in Body Weight at Week 88 (Randomization (Week 36), Week 88): Tirzepatide MTD -6.7 percent change (Standard Error 0.52) vs Placebo 14.8 percent change (Standard Error 0.53)
Liraglutide (Saxenda)ApprovedPeptideGLP-1 receptorReliable signal
NCT02918279: Change in BMI SDS (Week 0, Week 56) (Week 0, week 56): Liraglutide 3.0 mg -0.25 SDS score (Standard Deviation 0.51) vs Placebo -0.02 SDS score (Standard Deviation 0.54)
NCT01557166: Change From Baseline in Apnoea-hypopnoea Index (AHI) (Week 0, Week 32): Liraglutide 3.0 mg -12.22 events/hour (Standard Deviation 23.34) vs Placebo -6.08 events/hour (Standard Deviation 25.9)
Naltrexone / Bupropion (Contrave)ApprovedSmall moleculeOpioid receptor / dopamine (combination), Dopamine/norepinephrine transporternot yet graded
NCT03374956: Change in Total Body Weight (baseline to 12 weeks): Intervention Group -7.7% (IQR -11 to -4.7) vs Control Group -6.5% (IQR -11 to -2.3) phase 3 result · pivotal pending
Orforglipron (Foundayo)ApprovedSmall moleculeGLP-1 receptorPartial signal
NCT05872620: Body weight change from baseline to Week 72 (treatment-regimen estimand): -9.6% orforglipron 17.2 mg vs -2.5% placebo (p<.001 for all orforglipron doses vs placebo); HbA1c change: -1.66% (17.2 mg) vs -0.47% placebo (p<.001)
NCT05803421: Primary endpoint, time to first MACE-4 (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalisation for unstable angina), non-inferiority with margin 1.8 on the upper 95% CI bound of the hazard ratio: 57/1358 (4.2%) orforglipron vs 67/1343 (5.0%) insulin glargine; HR 0.84 (95% CI 0.59 to 1.20; p<0.0001 for non-inferiority), met.
Orlistat (Xenical)ApprovedSmall moleculePancreatic/gastric lipaseWeak signalNo reviewed efficacy summary in this indication
Phentermine / Topiramate (Qsymia)ApprovedSmall moleculeNoradrenergic/anticonvulsant (combination)Reliable signal
NCT00553787: Percent Weight Loss From Baseline to Week 56 (Baseline to 56 weeks): VI-0521 Mid 7.81% (Standard Error 0.365) | VI-0521 Top 9.84% (Standard Error 0.275) vs Placebo 1.24% (Standard Error 0.277)
NCT00554216: Percent Weight Loss From Baseline to Week 56 (baseline to 56 weeks): VI-0521 Low 5.1% (Standard Error 0.538) | VI-0521 Top 10.92% (Standard Error 0.392) vs Placebo 1.55% (Standard Error 0.395)
Semaglutide (Wegovy Tablets)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Semaglutide (Wegovy)ApprovedPeptideGLP-1 receptorReliable signal
NCT03574597: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke (From randomisation (week 0) up to 240 weeks): Semaglutide 569/8803 vs Placebo 701/8801
NCT03548935: Change in Body Weight (%) (Baseline (week 0) to week 68): Semaglutide 2.4 mg — In-trial observation period: -15.6% (Standard Deviation 10.1); On-treatment observation period: -16.9% (Standard Deviation 9.4) vs Placebo — In-trial observation period: -2.8% (Standard Deviation 6.5); On-treatment observation period: -3.1% (Standard Deviation 6.4)
Setmelanotide (Imcivree)ApprovedPeptideMC4RWeak signal
NCT05774756: Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen (Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)): Setmelanotide -16.51 Percent change (Standard Error 1.401) | Placebo 3.32 Percent change (Standard Error 1.984)
NCT03287960: Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) (Week 52): Setmelanotide (Entire Study) 45.5% (95% CI 19.96 to 72.88)
Tirzepatide (Mounjaro)
Approved(overall)
PeptideGLP-1/GIP receptor (dual)
Reliable signal(overall)
No reviewed efficacy summary in this indication
AleniglipronPhase 3Small moleculeGLP-1 receptorPartial signal
NCT06703021: Placebo-adjusted mean weight loss 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks (both p<0.0001)
ASC30Phase 3Small moleculeGLP-1 receptorPartial signal
NCT07002905: Placebo-adjusted mean weight loss at Week 13: 5.4% (20mg), 7.0% (40mg), 7.7% (60mg) ASC30, all p<0.0001 vs placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06712836: Percent change in body weight at week 28 (Part A): berobenatide 0.4, 0.6, 0.9 and 1.2 mg weekly -6.41%, -8.36%, -11.29% and -12.45% vs placebo +1.67%; placebo-adjusted -8.09% to -14.13%, all p<0.0001 (CT.gov posted results).
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)Partial signal
NCT06973681: Placebo-adjusted LS-mean body weight reductions of 10.77% to 19.78% across BGM0504 dose groups (120 Chinese adults with obesity)
BofanglutidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT03856047: Change in Body Weight (%) (From baseline (week 0) to week 26): Cagrilintide 0.3 mg -6.1% (Standard Deviation 3.9) | Cagrilintide 0.6 mg -6.9% (Standard Deviation 5.4) | Cagrilintide 1.2 mg -8.5% (Standard Deviation 5.4) | Cagrilintide 2.4 mg -9.5% (Standard Deviation 6.2) | Cagrilintide 4.5 mg -10.8% (Standard Deviation 5.5) vs Liraglutide 3.0 mg -8.5% (Standard Deviation 5.6) | Pooled Placebo -3% (Standard Deviation 5.2)
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT05813925: Change in body weight at week 68: -18.4% (SE 0.7) CagriSema vs -11.9% (SE 0.7) semaglutide alone; ETD -6.5 percentage points (95% CI -8.4 to -4.6; p<0.0001)
DA-302168SPhase 3Small moleculeGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
EcnoglutidePhase 3PeptideGLP-1 receptorReliable signal
NCT05813795: Co-primary 1, percent change in body weight from baseline to week 40 (treatment-policy estimand): ecnoglutide 1.2 mg -9.1%, 1.8 mg -10.9%, 2.4 mg -13.2% vs placebo +0.1%; treatment differences -9.2% (97% CI -11.0 to -7.5), -11.1% (-13.1 to -9.1) and -13.3% (-15.3 to -11.3); all p<0.0001, met. Co-primary 2, weight reduction of at least 5% at week 40: 77%, 84% and 87% vs 16%; differences 60% (98% CI 50 to 71), 68% (58 to 78) and 70% (61 to 80); all p<0.0001, met.
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT05997576: Body weight vs placebo in overweight or obese adults (pivotal Phase 3): CSPC states the product significantly reduced body weight compared with placebo; no figures released. The announcement does not report the co-primary proportion with at least 5% weight loss (CSPC announcement, 13 October 2025).
EfpeglenatidePhase 3PeptideGLP-1 receptorReliable signal
NCT06174779: Percent change in body weight from baseline at Week 40: -9.75% (efpeglenatide/HM11260C) vs -0.95% (placebo); least-squares mean difference -8.13 percentage points, statistically significant
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signalNo reviewed efficacy summary in this indication
EloralintidePhase 3PeptideAmylin receptorReliable signal
NCT06230523: Body weight, percent change from baseline at Week 48: eloralintide 1 mg -9.4%, 3 mg -12.4%, 6 mg -17.6%, 9 mg -20.1%, 6/9 mg -19.9% and 3/6/9 mg -16.5% vs placebo -0.4%.
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)Reliable signal
NCT06525935: Placebo-adjusted weight loss at Week 48 (efficacy estimand), 24 mg CT-388: 22.5% (p<0.001); treatment-regimen estimand: 18.3% (p<0.001)
HDM1002Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
HDM1005Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
LenbelintidePhase 3PeptideAmylin receptorPartial signalNo reviewed efficacy summary in this indication
Maridebart Cafraglutide (MariTide)Phase 3PeptideGLP-1R agonist; GIPR antagonistReliable signal
NCT05669599: Primary endpoint percent change in body weight baseline to week 52 (treatment policy estimand): -12.3% to -16.2% across doses vs -2.5% placebo (obesity cohort); -8.4% to -12.3% vs -1.7% placebo (obesity-diabetes cohort)
MazdutidePhase 3PeptideGLP-1/glucagon receptor (dual)Reliable signal
NCT05607680: Co-primary 1, percent change in body weight from baseline to week 32 (treatment-policy estimand): mazdutide 4 mg -10.09% (95% CI -11.15 to -9.04), 6 mg -12.55% (95% CI -13.64 to -11.45) vs placebo +0.45% (95% CI -0.61 to 1.52); P<0.001 for both doses vs placebo, met. Co-primary 2, weight reduction of at least 5% at week 32: 73.9% (4 mg) and 82.0% (6 mg) vs 10.5% (placebo); P<0.001 for both doses vs placebo, met.
MDR-001Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
MibavademabPhase 3Monoclonal antibodyLeptin receptorPartial signalNo reviewed efficacy summary in this indication
OlatorepatidePhase 3PeptideGLP-1/GIP receptor (dual)Reliable signal
NCT06839664: Co-primary endpoints met at Week 48: up to 19.3% mean weight loss with olatorepatide from baseline (dose range 5/10/15mg); up to 97.2% of participants achieved ≥5% weight loss, statistically significant vs placebo.
PetrelintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)Partial signal
NCT06662539: Primary endpoint met: statistically significant weight reduction vs placebo at week 28 in all five dose arms; up to 10.7% mean reduction at week 42 vs 1.7% with placebo (ZUPREME-1, 2026-03-05).
RAY1225Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
RetatrutidePhase 3PeptideGLP-1/GIP/glucagon receptor (triple)Partial signal
NCT05929079: Primary endpoint, percent change in body weight from baseline to week 80 (treatment-regimen estimand): retatrutide 9 mg -16.8% and 12 mg -18.8% vs placebo -5.1%; treatment differences -11.8% (95% CI -13.7 to -9.8) and -13.8% (95% CI -15.8 to -11.8); p<0.0001 for both, met. Key secondary, 4 mg vs placebo: -11.9% vs -5.1% (difference -6.9%, 95% CI -8.7 to -5.1; p<0.0001). The registered AHI primary in the sleep apnea subset is not reported in the paper abstract.
NCT05931367: Co-primary 1, WOMAC pain subscale change to week 68 (treatment-regimen estimand): retatrutide 9 mg -4.0 points (-67.2%), 12 mg -3.7 points (-62.6%) vs placebo -2.1 points (-35.1%); statistically significant for each dose per the sponsor (p not printed), met. Co-primary 2, percent change in body weight to week 68: 9 mg -20.0%, 12 mg -23.7% vs placebo -4.6%; statistically significant for each dose per the sponsor (p not printed), met.
RibupatidePhase 3PeptideGLP-1/GIP receptor (dual)Reliable signal
NCT06396429: Mean weight loss at Week 48 (treatment policy estimand): up to 17.7% with HRS9531 (16.3 percentage points placebo-adjusted); up to 88.0% of HRS9531-treated participants achieved at least 5% weight loss
Safiglipron (HRS-7535)Phase 3Small moleculeGLP-1 receptorReliable signal
NCT06904105: Percent body-weight change at week 44, treatment-policy estimand (prespecified primary): -8.0% (120 mg) and -9.8% (180 mg) vs -2.4% placebo, superiority stated as met (no p-value given). Proportion with at least 5% weight loss at week 44 (registry primary): 58.6% (120 mg) and 68.2% (180 mg); placebo rate and significance not reported.
SurvodutidePhase 3PeptideGLP-1/glucagon receptor (dual)Partial signal
NCT06066515: Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-1, primary analysis, treatment-regimen estimand): -13.0% survodutide 6.0 mg and -12.2% 3.6 mg vs -5.4% placebo; body weight reduction of at least 5%: 71.9% and 72.6% vs 46.3% (P<0.001 for all comparisons with placebo).
NCT06066528: Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-2, primary analysis, treatment-regimen estimand): -9.8% survodutide 6.0 mg and -8.2% 3.6 mg vs -3.9% placebo; body weight reduction of at least 5%: 64.5% and 57.6% vs 35.1% (P<0.001 for all comparisons with placebo).
TesofensinePhase 3Small moleculeNoradrenaline/dopamine/serotonin reuptakeReliable signal
NCT00394667: After 24 weeks, mean weight loss with diet and placebo was 2.0%, while tesofensine doses produced significantly greater reductions of 4.5%, 9.2% and 10.6% respectively.
UBT251Phase 3PeptideGLP-1/GIP/glucagon receptor (triple)not yet gradedNo reviewed efficacy summary in this indication
VCT220Phase 3Small moleculeGLP-1 receptorPartial signal
NCT06939296: Primary endpoint met: 52-week weight loss about 12.2% and 12.4% vs 1.3% with placebo (2026-05-18).
NCT07011797: Phase 2 trial, explicitly named as NCT07011797: primary endpoints met, up to 11.5% weight loss at 36 weeks with CX11 (oral GLP-1 receptor agonist), ongoing weight loss without plateau; gastrointestinal AEs the most common safety finding.
VK2735Phase 3PeptideGLP-1/GIP receptor (dual)Reliable signal
NCT06828055: Primary endpoint (mean % body weight change from baseline at 13 weeks): up to -12.2% with oral VK2735 vs -1.3% placebo; placebo-adjusted -10.9%, p<0.0001
ZenagamtidePhase 3PeptideGLP-1/amylin receptor (dual)Weak signal
NCT06064006: Primary outcome, safety (number of treatment-emergent adverse events; no formal efficacy test). Secondary endpoint, estimated mean bodyweight change vs placebo: -24.3% vs -1.1% at week 36 (60 mg), -22.0% vs 1.9% (20 mg, week 36), -16.2% vs 2.3% (5 mg, week 28), -9.7% vs 2.0% (1.25 mg, week 20); p<0.0001 (Parts A-D), p=0.0003 (Part E) (Lancet 2025).
ZovaglutidePhase 3PeptideGLP-1 receptorReliable signal
NCT07020884: Percentage change in body weight from baseline at 24 weeks: -10.6% (80mg monthly), -13.8% (160mg monthly), -12.5% (80mg biweekly), -14.4% (160mg biweekly) vs -2.4% (placebo); p<0.0001.
Efsubaglutide AlfaPhase 2/3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06732960: Efsubaglutide Alfa produced a mean weight reduction of 7.16% (95% CI: -8.08 to -6.24) versus 0.86% with placebo. Overall, 82.5% of Efsubaglutide-treated participants achieved >=5% weight loss (vs. 0% placebo).
ABBV-295Phase 2PeptideAmylin receptorWeak signalFeatured results are safety only in this race
Apitegromab (Isembyld)Phase 2Monoclonal antibodyMyostatin (pro/latent form)Partial signal
NCT06445075: Change from baseline in total Lean Body Mass at 24 weeks: -1.6 kg (-3.4 lbs) with apitegromab+tirzepatide vs -3.5 kg (-7.6 lbs) with placebo+tirzepatide; difference 1.9 kg (4.2 lbs) less lean-mass loss with apitegromab, i.e. 54.9% relative preservation (p=0.001).
ARD-101Phase 2Small moleculeBitter taste receptor (gut)Partial signal
NCT05121441: General-obesity Phase 2 (n=20): ARD-101 produced a 2.51-fold greater reduction in hunger rating (Control of Eating Questionnaire) vs placebo; p=0.015
AT-7687Phase 2PeptideGIPR antagonistnot yet gradedNo reviewed efficacy summary in this indication
AZD9550Phase 2PeptideGLP-1/glucagon receptor (dual)Partial signalNo reviewed efficacy summary in this indication
BGM1812Phase 2PeptideAmylin/calcitonin receptor (dual)Weak signal
NCT07224399: Placebo-adjusted weight loss 0.2% to 9.2% (LS mean) across dose groups (0.3 to 7.2 mg once weekly for 1 to 4 weeks); no serious adverse events (sponsor-reported, 7 August 2026)
BI 3034701Phase 2PeptideGLP-1/GIP/NPY2 receptor (triple)Weak signalNo reviewed efficacy summary in this indication
BimagrumabPhase 2Monoclonal antibodyActivin/myostatin type II receptorPartial signal
NCT05616013: Change From Baseline in Body Weight at Week 48 (Baseline, Week 48): 30 mg/kg Bimagrumab -9.25 kilogram (kg) (Standard Error 1.33) | 10 mg/kg Bimagrumab + 1.0 mg Semaglutide -12.73 kilogram (kg) (Standard Error 1.29) | 10 mg/kg Bimagrumab + 2.4 mg Semaglutide -14.31 kilogram (kg) (Standard Error 1.34) | 30 mg/kg Bimagrumab + 1.0 mg Semaglutide -13.86 kilogram (kg) (Standard Error 1.29) | 30 mg/kg Bimagrumab + 2.4 mg Semaglutide -17.79 kilogram (kg) (Standard Error 1.29) vs Placebo + 1.0 mg Semaglutide -9.76 kilogram (kg) (Standard Error 1.25) | Placebo + 2.4 mg Semaglutide -14.24 kilogram (kg) (Standard Error 1.17)
Bremelanotide (Vyleesi)Phase 2PeptideMC4RReliable signal
NCT06565611: BMT-801 study (NCT06565611): weight reduction 4.4% (bremelanotide + tirzepatide) vs 1.6% (placebo); p<0.0001.
DapiglutidePhase 2PeptideGLP-1/GLP-2 receptor (dual)Partial signal
NCT05788601: NCT05788601, primary endpoint (% change in body weight, baseline to week 12): 6 mg dapiglutide vs placebo, difference −2.1%; p=0.076. missed
ECC4703Phase 2—Thyroid hormone receptor beta (THRβ)not yet gradedNo reviewed efficacy summary in this indication
Ecnoglutide (VRB-101)Phase 2PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
EnobosarmPhase 2Small moleculeAndrogen receptor (selective)Partial signal
NCT06282458: Change in total lean body mass at 16 weeks (day 112), enobosarm+semaglutide vs placebo+semaglutide: 71% relative reduction in lean mass loss (p=0.002); 27% greater fat loss vs control
ERX1000Phase 2Small moleculeLeptinWeak signalNo reviewed efficacy summary in this indication
Garetosmab (Pasatru)Phase 2Monoclonal antibodyActivin Anot yet gradedNo reviewed efficacy summary in this indication
HM15275Phase 2PeptideGLP-1/GIP/glucagon receptor (triple)Weak signalFeatured results are safety only in this race
HRS-4729Phase 2PeptideGLP-1/GIP/glucagon receptor (triple)Weak signalFeatured results are safety only in this race
LAE102Phase 2Monoclonal antibodyActivin receptor type IIA (ActRIIA)not yet gradedNo reviewed efficacy summary in this indication
MacupatidePhase 2PeptideGIP receptornot yet gradedNo reviewed efficacy summary in this indication
Metreleptin (Myalept)Phase 2Protein / enzyme therapeuticLeptinPartial signalNo reviewed efficacy summary in this indication
NA-931Phase 2PeptideGLP-1/GIP/glucagon/IGF-1 receptors (quadruple)Partial signal
NCT06564753: Mean body weight reduction from baseline at Week 13: up to 13.8% at the 150 mg daily dose; 11.9% relative to placebo
NimacimabPhase 2Monoclonal antibodyCB1 receptornot yet gradedNo reviewed efficacy summary in this indication
NNC0519-0130Phase 2PeptideGLP-1/GIP receptor (dual)Partial signalNo reviewed efficacy summary in this indication
NNC0662-0419Phase 2PeptideGLP-1 / GIP / Amylin receptorsWeak signalNo reviewed efficacy summary in this indication
Orlistat / Acarbose (EMP16)Phase 2Small moleculeGI lipase + intestinal alpha-glucosidasePartial signalNo reviewed efficacy summary in this indication
THDBH120Phase 2PeptideGLP-1/GIP receptor (dual)Weak signalFeatured results are safety only in this race
BrenipatidePhase 1PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
KP405
Phase 1(overall)
PeptideGLP-1/GIP receptor (dual)
Partial signal(overall)
No reviewed efficacy summary in this indication

Large race: only the 72 furthest-along competitors are listed; 48 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Compare side by side

4 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(80 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tirzepatide (Zepbound) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (10)
November 2026 (4)
Phase 1ObesityActive not recruiting
Est. primary completion 2026-11 · NCT07299084 · CT.gov ↗
What to watch
Phase 3ObesityActive not recruiting
Est. primary completion 2026-11 · NCT06962280 · CT.gov ↗
What to watch
Phase 3ObesityActive not recruiting
Est. primary completion 2026-11 · NCT06914895 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2026-11-23 · NCT07740291 · CT.gov ↗
What to watch
December 2026 (6)
Phase 1ObesityRecruiting
Est. primary completion 2026-12 · NCT07803744 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2026-12 · NCT07373834 · CT.gov ↗
What to watch
Phase 1ObesityRecruiting
Est. primary completion 2026-12-31 · NCT06759701 · CT.gov ↗
What to watch
Phase 2ObesityRecruiting
Est. primary completion 2026-12-31 · NCT06802081 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2026-12-31 · NCT06721507 · CT.gov ↗
What to watch
Phase 4ObesityEnrolling by invitation
Est. primary completion 2026-12-31 · NCT07057310 · CT.gov ↗
What to watch
2027 (36)
January 2027 (1)
Early phase / not applicableObesityRecruiting
Est. primary completion 2027-01 · NCT07364175 · CT.gov ↗
What to watch
February 2027 (3)
Phase 4ObesityRecruiting
Est. primary completion 2027-02-01 · NCT07154719 · CT.gov ↗
What to watch
Phase 3ObesityRecruiting
Est. primary completion 2027-02-14 · NCT07481747 · CT.gov ↗
What to watch
Early phase / not applicableObesityActive not recruiting
Est. primary completion 2027-02-15 · NCT06484114 · CT.gov ↗
What to watch
March 2027 (2)
Early phase / not applicableObesityActive not recruiting
Est. primary completion 2027-03-01 · NCT07685834 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2027-03-20 · NCT06606821 · CT.gov ↗
What to watch
April 2027 (4)
Phase 2ObesityRecruiting
Est. primary completion 2027-04-01 · NCT06811324 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2027-04-02 · NCT07293325 · CT.gov ↗
What to watch
Phase 1/2ObesityRecruiting
Est. primary completion 2027-04-28 · NCT07463846 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2027-04-28 · NCT06854614 · CT.gov ↗
What to watch
May 2027 (2)
Phase 4ObesityActive not recruiting
Est. primary completion 2027-05 · NCT06191848 · CT.gov ↗
What to watch
Phase 2ObesityNot yet recruiting
Est. primary completion 2027-05-15 · NCT07292519 · CT.gov ↗
What to watch
June 2027 (3)
Early phase / not applicableObesityRecruiting
Est. primary completion 2027-06 · NCT07866183 · CT.gov ↗
What to watch
Phase 3ObesityNot yet recruiting
Est. primary completion 2027-06-11 · NCT07738276 · CT.gov ↗
What to watch
Phase 4ObesityNot yet recruiting
Est. primary completion 2027-06-30 · NCT07354880 · CT.gov ↗
What to watch
July 2027 (3)
Phase 2ObesityNot yet recruiting
Est. primary completion 2027-07 · NCT07671391 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2027-07 · NCT07438444 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2027-07-01 · NCT06803888 · CT.gov ↗
What to watch
August 2027 (3)
Phase 4ObesityActive not recruiting
Est. primary completion 2027-08 · NCT06864026 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2027-08-10 · NCT07588438 · CT.gov ↗
What to watch
Phase 2ObesityNot yet recruiting
Est. primary completion 2027-08-15 · NCT06732245 · CT.gov ↗
What to watch
September 2027 (5)
Phase 1ObesityActive not recruiting
Est. primary completion 2027-09 · NCT06734273 · CT.gov ↗
What to watch
Phase 2ObesityRecruiting
Est. primary completion 2027-09 · NCT06143956 · CT.gov ↗
What to watch
Phase 1ObesityRecruiting
Est. primary completion 2027-09-01 · NCT06575738 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2027-09-18 · NCT07218445 · CT.gov ↗
What to watch
Phase 2ObesityRecruiting
Est. primary completion 2027-09-30 · NCT06518837 · CT.gov ↗
What to watch
October 2027 (4)
Phase 3ObesityRecruiting
Est. primary completion 2027-10 · NCT06439277 · CT.gov ↗
What to watch
Phase 3ObesityActive not recruiting
Est. primary completion 2027-10 · NCT05556512 · CT.gov ↗
What to watch
Phase 4ObesityNot yet recruiting
Est. primary completion 2027-10-26 · NCT07893457 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2027-10-30 · NCT06861439 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2ObesityRecruiting
Est. primary completion 2027-11 · NCT07228741 · CT.gov ↗
What to watch
December 2027 (5)
Phase 1ObesityActive not recruiting
Est. primary completion 2027-12 · NCT06751589 · CT.gov ↗
What to watch
Phase 4ObesityEnrolling by invitation
Est. primary completion 2027-12 · NCT07707778 · CT.gov ↗
What to watch
Phase 2ObesityRecruiting
Est. primary completion 2027-12-01 · NCT06847399 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2027-12-03 · NCT07257484 · CT.gov ↗
What to watch
Early phase / not applicableObesityNot yet recruiting
Est. primary completion 2027-12-31 · NCT07382024 · CT.gov ↗
What to watch
2028 (18)
January 2028 (2)
Early phase / not applicableObesityNot yet recruiting
Est. primary completion 2028-01-12 · NCT07728318 · CT.gov ↗
What to watch
Phase 4ObesityActive not recruiting
Est. primary completion 2028-01-31 · NCT06801015 · CT.gov ↗
What to watch
February 2028 (3)
Early phase / not applicableObesityRecruiting
Est. primary completion 2028-02 · NCT07443956 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2028-02 · NCT07387796 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2028-02-25 · NCT07096908 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3ObesityRecruiting
Est. primary completion 2028-04 · NCT06937086 · CT.gov ↗
What to watch
May 2028 (3)
Phase 3ObesityRecruiting
Est. primary completion 2028-05 · NCT06937099 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2028-05 · NCT06857942 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2028-05-01 · NCT07633639 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2ObesityRecruiting
Est. primary completion 2028-06 · NCT05912621 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1ObesityRecruiting
Est. primary completion 2028-07 · NCT07065552 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2ObesityNot yet recruiting
Est. primary completion 2028-08-15 · NCT07747805 · CT.gov ↗
What to watch
September 2028 (2)
Phase 1ObesityRecruiting
Est. primary completion 2028-09-07 · NCT07868354 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2028-09-30 · NCT07589322 · CT.gov ↗
What to watch
December 2028 (4)
Phase 2ObesityNot yet recruiting
Est. primary completion 2028-12 · NCT06180616 · CT.gov ↗
What to watch
Phase 3ObesityNot yet recruiting
Est. primary completion 2028-12 · NCT07829198 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2028-12 · NCT07326111 · CT.gov ↗
What to watch
Phase 2/3ObesityNot yet recruiting
Est. primary completion 2028-12-01 · NCT07846865 · CT.gov ↗
What to watch
2029 (14)
March 2029 (1)
Phase 2ObesityNot yet recruiting
Est. primary completion 2029-03 · NCT07078838 · CT.gov ↗
What to watch
April 2029 (1)
Phase 4ObesityRecruiting
Est. primary completion 2029-04 · NCT07554638 · CT.gov ↗
What to watch
May 2029 (1)
Early phase / not applicableObesityRecruiting
Est. primary completion 2029-05-15 · NCT07574723 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2ObesityRecruiting
Est. primary completion 2029-06-30 · NCT06582875 · CT.gov ↗
What to watch
July 2029 (1)
Phase 4ObesityRecruiting
Est. primary completion 2029-07 · NCT07247084 · CT.gov ↗
What to watch
August 2029 (3)
Phase 4ObesityNot yet recruiting
Est. primary completion 2029-08-01 · NCT07630454 · CT.gov ↗
What to watch
Early phase / not applicableObesityRecruiting
Est. primary completion 2029-08-30 · NCT06885736 · CT.gov ↗
What to watch
Phase 2ObesityRecruiting
Est. primary completion 2029-08-31 · NCT06517212 · CT.gov ↗
What to watch
September 2029 (1)
Phase 4ObesityNot yet recruiting
Est. primary completion 2029-09-01 · NCT07715929 · CT.gov ↗
What to watch
October 2029 (3)
Phase 3ObesityNot yet recruiting
Est. primary completion 2029-10 · NCT07881432 · CT.gov ↗
What to watch
Phase 3ObesityRecruiting
Est. primary completion 2029-10 · NCT07881458 · CT.gov ↗
What to watch
Phase 2ObesityNot yet recruiting
Est. primary completion 2029-10-31 · NCT07349641 · CT.gov ↗
What to watch
December 2029 (2)
Phase 3ObesityRecruiting
Est. primary completion 2029-12 · NCT07817875 · CT.gov ↗
What to watch
Phase 4ObesityRecruiting
Est. primary completion 2029-12-31 · NCT07900074 · CT.gov ↗
What to watch
2030 (1)
February 2030 (1)
Phase 2ObesityActive not recruiting
Est. primary completion 2030-02-01 · NCT07693608 · CT.gov ↗
What to watch
2034 (1)
December 2034 (1)
Phase 2ObesityRecruiting
Est. primary completion 2034-12-31 · NCT07874828 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

20 December 2024ApprovalFDA approves Zepbound for obstructive sleep apnea in adults with obesity
US, FDA · Source ↗